-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 15, 2021, AbCellera announced that it has reached a multi-year, multi-target research cooperation and licensing agreement with Moderna
According to the terms of the agreement, AbCellera will use its antibody discovery technology platform to find therapeutic antibodies against the targets selected by Moderna (up to 6)
AbCellera is an artificial intelligence-driven antibody discovery company
Moderna is committed to developing vaccines and therapies based on mRNA technology
(The original text has been deleted)
Reference materials:
[1] AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines.